Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03340974 · ClinicalTrials.gov registry record · Phase 1
Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer
A Phase 1 study, sponsored by Galera Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT03340974 is a Phase 1 study that has completed, run by Galera Therapeutics. The registered enrollment target is 42 participants.
The verdict
NCT03340974, a Phase 1 study, has completed, sponsored by Galera Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of the phase I/II clinical study is to determine the best dose of fractionated stereotactic radiation therapy (SBRT) given either with Avasopasem manganese (GC4419) or placebo to patients who have been diagnosed with locally advanced pancreatic cancer.
Interventions
- DRUG Placebo
- DRUG GC4419
- RADIATION Stereotactic Radiation Therapy (SBRT) 50 Gy
- RADIATION Stereotactic Radiation Therapy (SBRT) 55 Gy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2018-02-12 |
| Est. Completion | 2021-05-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03340974
The ClinicalTrials.gov registry entry for NCT03340974 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galera Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03340974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03340974 about?
NCT03340974 is a clinical study titled "Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer". The purpose of the phase I/II clinical study is to determine the best dose of fractionated stereotactic radiation therapy (SBRT) given either with Avasopasem manganese (GC4419) or placebo to patients who have been diagnosed with locally advanced pancreatic cancer.
What is the current status of trial NCT03340974?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2018-02-12. Estimated completion is 2021-05-26.
What interventions are being tested in trial NCT03340974?
The interventions under investigation include: Placebo (DRUG), GC4419 (DRUG), Stereotactic Radiation Therapy (SBRT) 50 Gy (RADIATION), Stereotactic Radiation Therapy (SBRT) 55 Gy (RADIATION).
Who is sponsoring clinical trial NCT03340974?
This trial is sponsored by Galera Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.